Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Metrics to compare | RPRX_old | Peers Peers - average of corresponding metrics from companies closely matching RPRX_old: | Sector Sector - Average of metrics from a broad group of related - sector companies | Relationship RelationshipRPRX_oldPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |